Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa

NCT01786395 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

202

Enrollment

INDUSTRY

Sponsor class

Conditions

Retinitis Pigmentosa

Interventions

DRUG: UF-021
DRUG: Placebo

Sponsor

R-Tech Ueno, Ltd.